Big picture, chart/ TA

In the big picture Bexmarilimab is a novel treatment activating the body to protect itself via immunotherapy. Fatal diseases force to act at most effective ways, but there is a danger that the body itself may be hurt. Finally it is the question of balance - a fine adjustment.

"In combination with standard-of-care, and in both solid tumors and hematologic malignancies, bexmarilimab may improve the efficacy of current cancer treatments and bring the promise of immunotherapy to a broader population."

The clinical tests have been initiated on hematologic malignancies because of simplier test protocols by blood samples.

Chart sample and technical analysis

https://www.marketscreener.com/quote/stock/FARON-PHARMACEUTICALS-OY-24949011/graphics/ 

An interval of one week; typical start-up company behaviour 

  

 

Kommentit

Tämän blogin suosituimmat tekstit

Faronin käypä arvo: 100€/ SimplyWallSt

BexNova

ENNUSTE